Latest news
21-03-2023 - NIH U01 Call for Natural History and Biomarker Studies of Rare Neurodegenerative Diseases
This call for natural history and biomarker studies to enrich clinical trial designs has a one-off deadline for applications.
The purpose of this National Institutes of Health (NIH) funding opportunity announcement (FOA) is to support efficient natural history studies and/or biomarker studies that fill unmet needs for rare neurodegenerative diseases for children and adults. Through the support of prospective natural history and/or biomarker studies with high quality and interpretable data elements, the United States Food and Drug Administration (FDA) expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.
[...]